IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Chiropractic for Hypertension in Patients (CHiP)
This study has been completed.
Sponsor:
Palmer College of Chiropractic
Information provided by (Responsible Party):
Palmer College of Chiropractic
ClinicalTrials.gov Identifier:
NCT01020435
First received: November 24, 2009
Last updated: September 19, 2016
Last verified: September 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators propose a prospective randomized 2 arm parallel observer-blinded phase II clinical study comparing a distinct method of upper cervical chiropractic manipulation to a sham technique in 50 individuals with stage I hypertension (systolic blood pressure (SBP): 140-159 mm Hg; diastolic blood pressure (DBP):90-99 mm Hg).
| Condition | Intervention | Phase |
|---|---|---|
| Hypertension | Other: Spinal Manipulation Other: Sham Spinal Manipulation | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Upper Cervical Manipulation for Patients With Stage 1 Hypertension |
Resource links provided by NLM:
Further study details as provided by Palmer College of Chiropractic:
Primary Outcome Measures:
- Feasibility of conduction a full-scale randomized control trial to evaluate the efficacy of Toggle Recoil chiropractic manipulation for patients with stage 1 hypertension [ Time Frame: 6 weeks ]To assess the feasibility of conducting a full-scale randomized controlled trial to evaluate the efficacy of Toggle Recoil chiropractic manipulation for patients with stage I hypertension. We will assess: 1) the success of blinding clinic personnel to treatment allocation; 2) the ability to effectively use Academic Health Center faculty as research clinicians; 3) the ability to take blood pressure measurements according to protocol and keep clinic personnel blinded; 4) the ability to retain participants who are randomized to the placebo treatment (n=25) and the active treatment (n=25).
Secondary Outcome Measures:
- Estimate the effect size and variability of change in systolic and/or diastolic blood pressure [ Time Frame: 6 weeks ]To estimate the effect size and variability of change in systolic and/or diastolic blood pressure over a six week treatment period to use in planning a full-scale randomized controlled trial and to assess the believability of the placebo manipulation
| Enrollment: | 51 |
| Study Start Date: | October 2010 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Spinal Manipulation High Velocity
This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
|
Other: Spinal Manipulation
The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
|
|
Placebo Comparator: Sham Spinal Manipulation
The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
|
Other: Sham Spinal Manipulation
The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
Other Name: Sham
|
Detailed Description:
More than 50 million Americans suffer from hypertension, a disease with far-reaching public health impact causing or contributing to 7.1 million deaths yearly at an estimated annual incremental direct cost of $54 billion per year. Common treatments include antihypertensive medications and lifestyle modifications. While these treatments have been shown to be effective, only about 30% of hypertensive patients achieve blood pressure goals. Based on a recently published study (Bakris et al, 2007), one unique non-pharmaceutical approach may be a non-rotary type of upper cervical spinal manipulation to align the first cervical vertebra (atlas) performed by a doctor of chiropractic. We propose to conduct a similar study with a more commonly known chiropractic technique called Toggle Recoil. We propose a prospective randomized 2 arm parallel observer-blinded phase II clinical study comparing a distinct method of upper cervical chiropractic manipulation to a sham technique in 50 (25 in each group) individuals with Stage I hypertension (systolic blood pressure (SBP); 140-159 mm Hg or diastolic blood pressure (DBP):90-99 mm Hg). Patients will be seen by doctors of chiropractic twice each week for 6 weeks and outcomes will be collected at baseline, 3 weeks, and 6 weeks after enrollment. The primary outcome measure will be change in SBP and the primary endpoint will be at the week 6 assessment.
Eligibility| Ages Eligible for Study: | 21 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age > 21 and < 75
- Documented Stage I Hypertension
Exclusion Criteria:
- Cardiovascular disorders (Angina pectoris, symptom of CHD; Hemodynamically significant valvular heart disease; Second or Third degree heart block without pacemaker; Stroke, MI, CV surgery within the past 12 months; Claudication, Aortic Coarctation)
- Defibrillator
- Autoimmune Arthropathies
- Pregnancy
- Unwillingness to stop other forms of manual therapy during study
- Unwillingness to sign ICD or preliminary consent
- Intention to move from the area during the next 4 months
- Unwillingness to participate in any of the treatment groups
- Avg SBP<140 or >159mm Hg (AND) Avg DBP<90 or >99mm Hg
- Any single SBP > 160mm Hg or DBP> 100
- BMI > 40
- Prescription medications with increased risk for CVA
- Current use of anti-coagulant medication/blood thinners
- Active drug or alcohol addiction or abstinent < 1 year
- Psychiatric diagnosis that would limit patient compliance
- Serious concomitant medical illness
- Contraindication(s) to treatment
- Electrolyte abnormalities seen on lab test
- Renal Failure w/ creatinine >2.5mg/dL
- Abnormal Liver function tests
- Anemia with hematocrit < 30%
- Glucose in Urine
- Serum potassium <3.4 @ baseline
- S/S Renal artery stenosis
- Quebec Task Force Classification 4-9
- Self-reported Arnold Chiari malformation
- Spinal or paraspinal tumors
- Dx with disorder that exhibit spinal joint hypermobility (Marfan Syndrome, Ehlers-Danlos Syndrome, Osteogenesis imperfecta)
- Unstable endocrine disorders
- Osteoporosis
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01020435
Please refer to this study by its ClinicalTrials.gov identifier: NCT01020435
Locations
| United States, Iowa | |
| Palmer College of Chirpractic | |
| Davenport, Iowa, United States, 52803 | |
Sponsors and Collaborators
Palmer College of Chiropractic
Investigators
| Principal Investigator: | Christine M Goertz, DC, PhD | Palmer College of Chiropractic |
More Information
Additional Information:
Publications:
| Responsible Party: | Palmer College of Chiropractic |
| ClinicalTrials.gov Identifier: | NCT01020435 History of Changes |
| Obsolete Identifiers: | NCT01230372 |
| Other Study ID Numbers: |
CHiP |
| Study First Received: | November 24, 2009 |
| Last Updated: | September 19, 2016 |
Keywords provided by Palmer College of Chiropractic:
|
Hypertension |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on August 21, 2017